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Abstract: Fabry disease (FD) is a multisystem, X-linked disorder of glycosphingolipid 
metabolism caused by enzyme deficiency of α-galactosidase A. Affected patients have symptoms 
including acroparesthesias, angiokeratomas, and hypohidrosis. More serious manifestations 
include debilitating pain and gastrointestinal symptoms, proteinuria and gradual deterioration 
of renal function leading to end-stage renal disease, hypertrophic cardiomyopathy, and stroke. 
Heterozygous females may have symptoms as severe as males with the classic phenotype. Before 
2001, treatment of patients with FD was supportive. The successful development of enzyme 
replacement therapy (ERT) has been a great advancement in the treatment of patients with FD 
and can stabilize renal function and cardiac size, as well as improve pain and quality of life of 
patients with FD. In this review, we have provided a critical appraisal of the literature on the 
effects of ERT for FD. This analysis shows that data available on the treatment of FD are often 
derived from studies which are not controlled, rely on surrogate markers, and are of insufficient 
power to detect differences on hard clinical endpoints. Further studies of higher quality are 
needed to answer the questions that remain concerning the efficacy of ERT for FD.
Keywords: Fabry disease, agalsidase α, agalsidase β, Replagal, Fabrazyme, critical appraisal, 
evidence-based medicine
Introduction
Fabry disease (FD) is an X-linked inborn error of glycosphingolipid catabolism 
resulting from the deficient activity of the lysosomal hydrolase, α-galactosidase A 
(α-Gal A). The enzymatic defect leads to the accumulation of glycosphingolipids, 
mainly globotriaosylceramide (GL-3), in body fluids, in the lysosomes of endothelial, 
perithelial, and smooth-muscle cells of blood vessels, in ganglion cells, and in many 
cell types in the heart, kidneys, eyes, and most other tissues.1
Clinical manifestations in classically affected hemizygous males who have no 
detectable enzyme activity include early childhood or adolescent onset of pain 
(acroparesthesias) in the extremities, angiokeratoma in skin and mucous membranes, 
and hypohidrosis. Corneal and lenticular opacities are also seen as early findings. 
Gastrointestinal problems, such as diarrhea, constipation, and abdominal pain, are 
common. Endocrine abnormalities include thyroid disease and fertility problems 
in both males and females. With increasing age, proteinuria, hyposthenuria, and 
lymphedema appear. Severe renal impairment leads to hypertension and uremia. Death 
usually occurs from renal failure or from cardiac or cerebrovascular disease. Atypical 
hemizygotes with residual enzyme activity may have later onset of symptoms, and Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
70
 Alfadhel and Sirrs
such symptoms may be limited to the heart in some cases 
(the ‘cardiac variant’).1 Heterozygous females can be as 
severely affected as hemizygous males, although the range 
of symptoms varies widely. A frequent clinical finding in 
females is the characteristic whorl-like corneal epithe-
lial dystrophy observed by slit-lamp microscopy (cornea 
verticillata).1
Confirmation of the clinical diagnosis in males requires 
the demonstration of deficient α-Gal A activity in plasma, 
leukocytes, or fibroblasts, or increased levels of GL-3 in 
plasma or urinary sediment. Heterozygous females may have 
intermediate or even normal levels of enzymatic activity and 
accumulated substrate, so accurate diagnosis of heterozygous 
females requires identification of a molecular lesion in the 
α-Gal A gene or by linkage analysis in families with an 
affected male.1
Before 2001, treatment of patients with FD was 
exclusively supportive. Advancement of molecular genetic 
techniques led to the development of enzyme replacement 
therapy (ERT). There are two forms of (ERT): agalsidase α 
(AGALA) (Replagal®; Shire Human Genetic Therapies Inc, 
Cambridge, MA) and agalsidase β (AGALB) (Fabrazyme®; 
Genzyme Corporation, Cambridge, MA). Table 1 compares 
the two forms of available ERT.2,3 In this review, we have 
examined the literature on the effects of ERT for FD with 
the aim of providing a critical appraisal of the literature and 
its limitations.
Methods
We formulated a comprehensive search strategy in an 
attempt to identify all relevant studies published in the 
English language. An Ovid search was conducted using the 
Ovid databases: MEDLINE® (1950 to present with daily 
update) and Embase (1980 to date). Details of the search 
strategy are presented in Table 2. After the exclusion of 
case reports, studies not on ERT effects, studies not on FD, 
and general reviews on FD, 41 studies were included in this 
review.2, 4–7, 9–45 Abstracts were reviewed using the evidence 
grading system developed by Oxford Centre for Evidence-
based Medicine – Levels of Evidence (March 2009).46
Results
Factors that complicate  
interpretation of data
The grading of the evidence available on ERT for FD is 
listed in Table 3. A summary of the effects of ERT on vari-
ous Fabry-related endpoints is provided in Table 4. While 
reading through the information in the tables, it is important 
to remember that, regardless of whether a disease is rare or 
common, studies of adequate quality are needed to distin-
guish true findings from false findings. There is a real need 
to critically appraise the literature available on ERT for FD 
for several reasons listed below.
The high cost of eRT
Given the recommended dosage of AGALA and AGALB, 
the cost of treatment for a 70-kg patient exceeds US$200,000 
per year, and therefore, accurate information on the effects 
of ERT on hard clinical outcomes, such as the need for 
dialysis and stroke, is needed to be able to calculate the 
cost-effectiveness of therapy.
Lack of accurate natural history data
The studies of natural history regarding FD are very 
heterogeneous,47–53 resulting in imperfect understanding 
of the natural history of this rare disease. As most of the 
publications on FD do not contain a prospective, untreated 
control group, accurate natural history data are essential 
for determining the effect of therapy. For example, natural 
history data are discordant when considering the risk of 
stroke. Studies report that rates of stroke range from 4.2% to 
27% in females and from 6.7% to 24% in males. Even more 
confusing, successive publications from the same registry 
cite conflicting rates of stroke.47,48,50,51 The data on glomeru-
lar filtration rate (GFR) are just as confusing. For example, 
in one of the earliest reports on the natural history of FD,   
a retrospective chart review of males with FD estimated 
annual decline in estimated GFR at 12.2 mL/min per year.54 
Another study that summarized the results of three separate 
clinical trials that were conducted at different times and 
sites showed rates of decline ranging from 2.9 to 7 mL/min/
Table 1 Comparison between characteristics of AGALA and AGALB
AGALA AGALB
Production Human cell line by gene activation2,3 Chinese hamster ovary cells by recombinant techniques3
Dose 0.2 mg/kg/2 weeks 1 mg/kg/2 weeks
Duration of an infusion 40 min 2–4 h
Premedication None, unless patient has infusion reactions Antipyretic and/or antihistamine
Abbreviations: AGALA, agalsidase α; AGALB, agalsidase β.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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year/1.73 m2 in untreated males.44 As most of the reported 
literature on FD and ERT does not include a control group, 
the lack of accurate natural history information makes the 
effects of ERT difficult to interpret.
Conflicting prevalence data
Several studies investigating FD in dialysis patients in the 
United States and European registries reported prevalence 
to be 0.0168% and 0.0188% respectively,55 with the preva-
lence among dialysis males about 0.027% in both registries 
while a study in Austria reported higher results in dialysis 
males with a prevalence of 0.264% and prevalence in overall 
dialysis patients of 0.161%.56 A recent systematic review 
demonstrated that the overall FD prevalence on dialysis was 
0.33% in males and 0.10% in females.57 These data may 
underestimate the prevalence of FD in females on dialysis, 
however, as 91% of the screening studies in women were 
performed using α-Gal A activity analysis as the primary 
screening method, which is unreliable for detection of FD in 
female patients.57 Newborn screening studies showed that the 
incidence of Fabry mutations in Taiwan Chinese and Italian 
populations to be 1:1400 and 1:3100 males, respectively,58,59 
which is 15–30 times higher than previous estimates.1 More 
accurate data on disease prevalence are needed to identify 
the degree of ascertainment bias which may be present in 
the large multinational registries that provide most of the 
available data on the effects of ERT therapy.
Unknown impact of antibodies
Treatment of Fabry patients may induce the formation of 
neutralizing antibodies toward AGALA and AGALB, and 
this may influence the effects of therapy. Antibody formation 
is more common in males.7 The significance of these antibod-
ies on clinical endpoints, though, is unclear as most of the 
studies on this have evaluated only surrogate endpoints and 
not all studies report on the presence of antibodies. One trial 
in male patients showed that the urinary GL-3 levels failed to 
decline in patients with IgG antibodies, whereas a reduction 
could be detected in patients without IgG antibodies.6,7 This 
is in contrast to a study showing that 1.0 mg/kg of AGALB 
did reduce cardiac mass in small group of patients who 
were antibody positive. Using a surrogate marker like GL-3, 
which is an unreliable indicator of disease severity, may 
contribute to the poor understanding of inhibitory effect of 
IgG antibodies.53,60
When evaluating the medical literature on the effects of 
ERT on disease activity in FD, it is important to look critically 
for certain points including 1) the presence of a concurrent 
control group rather than using conflicting retrospective 
natural history data, 2) clear delineation of the origins of 
the patient cohort including a discussion of the number of 
subjects who were excluded from analysis and the reasons 
for exclusion, 3) use of hard clinical endpoints, appropriate 
randomization and blinding techniques, and 4) clear descrip-
tion of the power of the study to detect a significant difference 
in the primary outcome. As these features seem to be a basic 
requirement of any data evaluating a therapeutic modality, 
many of these key points are missing in the available data 
on ERT for FD.
Grading of evidence
Seventy-one percent of the studies were graded as Grade 4 
or higher (see Table 3). Only one study achieved Grade 1,25 
although several achieved Grade 2.4,5,10,11,17,18,24,34,44
The single Grade 1 study25 has a placebo-controlled and 
blinded design, but nonetheless has significant limitations. 
The primary endpoint of this study was to show the effects 
of ERT on a composite clinical endpoint, which included 
renal, cardiac, and neurological events. Although the effects 
of AGALB on the composite outcome were of borderline sig-
nificance (P = 0.06), secondary analyses of protocol-adherent 
patients adjusted for baseline proteinuria demonstrated a more 
Table 2 Search strategy
Medline (Ovid SP) PubMed Embase
Search by disease (limit to human and english) 2800 980 3766
Limit to therapy 557 195 1106
Limit to clinical trial 72 62 273
exclusions of case reports, studies not on eRT  
effect, not on FD, and general reviews on FD
30 20 231
Final included 41
Notes: we formulated a comprehensive search strategy in an attempt to identify all relevant studies published in english language. An Ovid search was conducted using 
the Ovid databases: MeDLiNe® 1950 to present with daily update and embase (1980 to date). The following search terms were used: Fabry* disease, enzyme replacement, 
agalsidase, Replagal, and Fabrazyme. These terms were entered as MeSH subject heading terms as well. ADJ2 = words closely adjacent within two words of each other; 
$ = truncation, any number of characters; and Boolean operator Or/And were used to combine search terms. Filters for randomized-controlled trials were used. in addition, 
reference lists of relevant published articles were searched to make the search as complete as possible.
Abbreviations: FD, Fabry disease; MeSH, Medical Subject Headings; eRT, enzyme replacement therapy.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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pronounced treatment effect compared with the placebo group 
(P = 0.034). Although these data are encouraging, the raw data 
suggest that the effects of therapy on the composite outcome 
were primarily driven from one of the renal endpoints which 
was, in fact, a surrogate measure (33% increase in serum 
creatinine) rather than hard renal endpoints like dialysis or 
transplantation. The 33% increase in serum creatinine com-
prised 10/14 events in the AGALB group and 7/13 events in 
the placebo group. Another possible limitation of this study 
is that only about one-third of the patients in each group were 
receiving antiproteinuric therapy with angiotensin-converting 
enzyme (ACE) inhibitors or angiotensin-receptor blockers 
(ARBs). As therapy directed at the renin-angiotensin system 
is beneficial in Fabry nephropathy,61 the underutilization of 
such supportive therapies may have served to increase the 
perceived benefit of ERT.
To measure the outcome of interest, 98% of the studies 
used surrogate endpoints. Surrogate measures are often 
used when the disease is so rare or the desired outcome is 
so far in the future that it would take an unreasonably long 
follow-up period to obtain a sufficient number of outcomes. 
Even though the association between the surrogate measure 
and the true outcome may be biologically plausible, using 
the surrogate measure may produce misleading results if the 
association with the true outcome is not based on hard end-
points. The surrogate marker used in the first large study of 
AGALB was GL-3.5 This trial demonstrated that therapy with 
AGALB led to clearance of GL-3 from biopsy specimens of 
the kidney, heart, and skin. Although these results were used 
to gain approval for AGALB in the United States, subsequent 
studies have shown that the relationship between GL-3 and 
clinical endpoints are less clear.53,62
Many of the publications include data obtained by 
cross-sectional surveys,47,48 database registries12,35,40,42,43,49–52 
or historical cohorts,53 which are subject to different 
sources of bias including selection bias, ascertainment 
bias, reporting bias, survivor bias (based on the early death 
of more severely affected patients), incomplete and miss-
ing data (leading to misclassification), and importantly, 
the absence of simultaneous controls. There are two large 
multinational registries: the Fabry Outcome Survey (FOS) 
sponsored by Shire Human Genetic Therapies, manufacturer 
of AGALA, and the Fabry Registry sponsored by Genzyme 
Corporation, manufacturer of AGALB. There are numer-
ous publications from these registries which contribute to 
the medical literature on FD.12,35,39,41,42,63 As these registries 
are able to combine large number of patients from around 
the world with different genetic backgrounds, they provide Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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valuable information on the progression of Fabry-related 
complications and the effects of ERT, and can also help 
to define some of the less frequent manifestations of an 
already rare disease. However, there are some problems 
with the data inherent in both the registries in that data col-
lection is voluntary and, therefore, incomplete. This results 
in publications where the total number of patients included 
in the studies is often less than the total number of eligible 
patients, which can compromise conclusions drawn from 
these studies. For example, one study from the FOS includes 
only 201 patients, while at the time of analysis, 608 patients 
(358 receiving ERT) were enrolled in the registry.35 Another 
publication included only 71 men and 59 women, while at 
time of analysis, 3182 patients were enrolled in the registry.63 
Although it is admittedly difficult to perform high-quality 
randomized studies in diseases of low prevalence, it is not 
impossible in that such studies have been done in other types 
of kidney diseases with similar prevalence to FD.64
effects of eRT
The major effects of ERT on different organ systems are 
summarized in Table 4 along with the limitations of the 
studies from which these effects have been determined. In 
summarizing the literature to date on ERT for FD, some 
conclusions can be drawn. It is clear that FD is a multisystem, 
progressive disorder in both males and females.49 It is clear 
that ERT is an effective treatment for neuropathic pain in 
FD.4 It is also clear that ERT can stabilize renal function or 
at least slow the decline of renal function in many patients 
with Fabry nephropathy12,25,28,35,36,38,41,44 and stabilize or 
improve surrogate parameters like cardiac size in those with 
cardiomyopathy.12,20,29,34
Discussion
Unanswered questions about  
the treatment of FD
There are many unanswered questions such as the 
following:
1.  What is the role of risk factor modification in the preven-
tion of Fabry-related complications? A cross-sectional 
study showed high prevalence of uncontrolled hyperten-
sion among adult patients with FD who are included in 
the FOS registry database.65 However, the cross-sectional 
nature of the study makes it impossible to infer a role of 
risk factor modification from this type of publication. 
A report describes an open-label, nonrandomized, pro-
spective evaluation of the effects of ACE inhibitor and 
ARB therapy that were shown to have beneficial effects 
on proteinuria and renal function in FD patients who are 
receiving AGALB given at 1 mg/kg/2 weeks.61 However, 
this observational study has a small sample size and 
should be confirmed in a larger population. At present, an 
open-  label, prospective, observational study (Fabrazyme 
and ARBs and ACE Inhibitor Treatment – FAACET) is 
exploring the hypothesis that titration of ACE inhibitors and 
ARBs to reduce urine protein excretion to ,500 mg/day in 
Fabry patients receiving AGALB (1 mg/kg every 2 weeks) 
will slow the progression rate of decline of GFR compared 
to controls. Details of this study are available at http://www.
clinicaltrials.gov/.
2.  What is the pathophysiology of the Fabry vasculopathy? 
One comprehensive review article showed that smooth 
muscle cells are a key player in the vasculopathy of FD. 
It concludes that the proliferation of smooth muscle cells 
and GL-3 storage result in higher intima-media thickness, 
increased reactive oxygen species production as well as 
enhanced nitric oxide production, which may result in 
different findings with respect to endothelial-activation 
markers, which can be severely enhanced in the context 
of other vascular risk factors.66 However, this article 
showed that most studies carried out on evaluating Fabry 
vasculopathy were limited to case reports or case-control 
studies making it difficult to infer causality.
3.  What is the role of ERT in the primary prevention setting? 
It has been established that pediatric patients have a signifi-
cant disease burden with renal dysfunction and that cardiac 
involvement is detectable in adolescents with FD.67,68 
Another case series showed that signs of cardiac involve-
ment are evident at an early age. Seven of 20 children 
included in this study, aged from 6.2 to 17.4 years, had 
left ventricular hypertrophy.69 Although it is clear that 
pediatric patients do have detectable disease, ERT would 
only be required in the primary prevention setting if disease 
manifestations are irreversible. It is clear that some disease 
manifestations, like renal and cardiac involvement, can be 
stabilized if diagnosed early in the disease course. What is 
not clear, though, is the reversibility of other Fabry-related 
complications including the risk of stroke. The extent to 
which ERT can reverse progressive organ damage must be 
determined separately for each organ system. This question 
is critical when trying to establish the appropriate age of 
initiation of ERT. Currently, there is an ongoing pediatric 
primary prevention study to study the effectiveness of two 
alternative dosing AGALB dosing regimens in treatment 
of naive, male pediatric patients (details are available at 
http://www.clinicaltrials.gov/).Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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4.  What is the appropriate dose of ERT? There are few dose 
ranging studies for either product. One small study by 
Vedder et al7 suggested that 1.0 mg/kg of AGALB resulted 
in a more robust decline in GL-3 than does infusion of 
AGALA or AGALB at a dose of 0.2 mg/kg. The authors 
conclude that the higher dose of AGALB overcomes the 
negative effects of antibody formation. Lubanda et al31 
showed that in kidney interstitial capillary endothelium, 
the GL-3 clearance was achieved in 100% of patients with 
1.0 mg/kg of dose compared to 90% with 0.3 mg/kg of 
dose. More information on the effects of different dosing 
regimens is needed for both AGALA and AGALB.
5.  Are the two existing ERT products equivalent? A single 
head-to-head trial using AGALB and AGALA at the same 
dose showed no difference in surrogate endpoints, such 
as reduction of the left ventricular mass, GFR, pain and 
decline in GL-3 levels, treatment failure, and antibody 
formation.6 However, there was no influence of antibodies 
on the reduction of urine GL-3 levels in patients treated 
with AGALB in contrast to the attenuated response 
seen in the pooled cohort treated with either AGALA or 
AGALB at 0.2 mg/kg/2 weeks.7 An ongoing independent 
observational study known as the Canadian Fabry Disease 
Initiative (details are available at http://clinicaltrials.gov/) 
includes an arm, where patients newly started on ERT 
are randomized to one of the two commercially available 
products at product monograph doses,70 and it will 
provide more data in the future on the relative effects of 
the two products.
Future developments
Although the ERT is a step forward in the management of 
FD, the requirement for frequent infusions, the enormous 
cost for lifelong therapy, the inability of ERT to traverse 
the blood–brain barrier, and uncertainty about the long-term 
effectiveness on hard clinical endpoints in Fabry patients 
make other modalities of treatment candidates for consider-
ation. Two such novel approaches are chaperone therapy71–75 
and gene therapy.76
Chaperone therapy is a novel approach that uses small 
molecules that specifically bind to and stabilize the func-
tional form or shape of a misfolded protein in the endoplas-
mic reticulum (ER) of a cell. When a protein (enzyme) is 
misfolded because of a genetic mutation, it becomes unable 
to adopt the correct functional shape. This misfolded protein 
is recognized by the quality control system in the cell and 
is destroyed, leading to a decreased amount of enzyme that 
gets transported from the cell’s ER to the cell’s lysosome, 
and hence, reduced enzyme activity. The binding of the chap-
erone molecule helps the protein fold into its correct shape. 
This allows the protein to be properly trafficked from the ER 
and distributed to the lysosome in the cell, thereby increas-
ing enzyme activity and cellular function and reducing 
substrate and stress on cells.77 The advantage of such an 
approach includes better biodistribution of therapeutic 
agents, and such agents are able to traverse through the 
blood–brain barrier unlike ERT. Chaperone therapies can be 
administered orally, which may reduce the impact on quality 
of life caused by the need for biweekly infusions of ERT. 
In a trial of 27 patients with FD, treated for up to 2 years 
with 1-deoxygalactonojirimycin (DGJ) or Migalastat, the 
drug was safe and well tolerated. Migalastat increased the 
leukocyte, kidney, and skin α-Gal A activities and reduced 
the substrate (GL-3) levels in the urine and kidney biopsies 
of 24 patients.78 Furthermore, the chaperone response of 
patients was similar to that predicted by models of in vitro 
responsiveness of α-Gal A gene mutations,78 suggesting 
that there may be an easy way to determine which patients 
would be appropriate for the use of chemical chaperones. 
In another study, the response of T cells in normal indi-
viduals or in Fabry patient’s to treatment with DGJ showed 
28% increase in α-Gal A activity, whereas the response in 
Fabry individuals was mutation dependent ranging from 
no increase to fully normal activity.71 Although these stud-
ies are promising, long-term trials looking at hard clinical 
endpoints are required.
Promising results have also been achieved in gene therapy 
experiments with the mouse model of FD. Adult Fabry model 
mice have been successfully treated by various viral vectors. 
Using adeno-associated viral vectors, long-term enzymatic 
and functional corrections in various organs of the Fabry 
mouse have been attained.79,80 One study showed a single neo-
natal injection was effective to inhibit GL-3 accumulation in 
mice. If these data can be replicated in humans, this approach 
may be useful to prevent major organ failure developing later 
in life in patients with FD.76 The advantages of gene therapy 
include persistent correction after a single procedure and 
cross-correction by enzymes secreted by organs. However, 
much work is still needed before this can be translated into 
the clinical setting.78
Conclusion
ERT for FD is a major step forward for patients and has revo-
lutionized care for patients with this fatal disease. However, 
as the field moves forward, questions need to be answered, 
some of which stem from the fact that most of the studies Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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are observational and/or uncontrolled. The availability of 
registries for FD currently is an excellent step to collect a 
large sample size. These registries could be used to draw 
participants for possible randomized-controlled studies which 
could generate Grade 1 data. Observational information 
from those registries, although useful to generate hypoth-
eses, should never replace data from randomized-controlled 
trial. Crossover studies are a useful approach, but they 
present ethical challenges given that, at the current time, 
disease-modifying therapy for FD other than ERT is not 
available outside the clinical trial setting. In future, innova-
tive approaches to research in rare diseases will be needed to 
obtain data of high quality while ensuring that there are no 
undue delays in translating the results of laboratory research 
into the clinical setting.
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